GREAT COMPANY BUT MS DRUG...TOUGH SELL

Quote
anonymous said:
Tootles and peace, what a loser! Go to work and get off this thread! The amount of time your trash talking and whining clearly show what low pos you really are. Or maybe your a female without anything in between your legs since you love to use the word Tootles! Have some class! Tootles!
Click to expand...


Maybe you are a loser with short dick or about to have gender change?
 






anonymous said:
what a dumb fuck you are with your response. The MS reps know exactly why your response is so laughable. I wish I could witness your first call.
Click to expand...

You didn't deny anything that poster said. Why don't you just teach us all the "MS" way. You sir, are a moron and a poor ambassador for your company. I am one of the lucky few that made it to Chicago, so by your reasoning, I am either internal OR an "MS" guru................... OR neither. Hmmmmm
 












anonymous said:
You didn't deny anything that poster said. Why don't you just teach us all the "MS" way. You sir, are a moron and a poor ambassador for your company. I am one of the lucky few that made it to Chicago, so by your reasoning, I am either internal OR an "MS" guru................... OR neither. Hmmmmm
Click to expand...

Gloating much you narcissistic moron? So not an insider nor MS SME - sounds like seat filler to me!
 












To the clown who said ocrelizumab is going to be "tough to sell" - you must be high. I've been in MS - for other companies (like I am now) - for 10 years and I've never seen the collective euphoria that I've seen for this one. I can't tell you how many docs who've told me "why would you treat with anything else?". You try to bring them back to a place of cautious optimism by pointing out how the safety profiles of Tysabri and Tecfidera looked stellar in the trials, but look how they turned out, docs turn right to Rituxan and say "no problems there". Hauser's presentation of Opera 1 and 2 at ECTRIMS got a standing ovation, and even whistling, from a crowd of about 5,000. It was insane. This one is going to be the easiest sell you've ever had, and like I said, this is coming from someone who's been working for one of your competitors on the research/clin dev side for 10 years.
 






anonymous said:
To the clown who said ocrelizumab is going to be "tough to sell" - you must be high. I've been in MS - for other companies (like I am now) - for 10 years and I've never seen the collective euphoria that I've seen for this one. I can't tell you how many docs who've told me "why would you treat with anything else?". You try to bring them back to a place of cautious optimism by pointing out how the safety profiles of Tysabri and Tecfidera looked stellar in the trials, but look how they

turned out, docs turn right to Rituxan and
say "no problems there". Hauser's
presentation of Opera 1 and 2 at ECTRIMS
got a standing ovation, and even whistling,
from a crowd of about 5,000. It was insane.
This one is going to be the easiest sell
you've ever had, and like I said, this is
coming from someone who's been working
for one of your competitors on the research/
clin dev side for 10 years.
Click to expand...

No way dude, I was in a trial and my pecker fell off. Also, grew a third nipple and became retahded.

Nawayaa
 












Top Bottom
Back
Quote